Webinar: KoNECT - Strategic approaches for first-in-human (FIH) studies and early clinical development

1:21:57

Webinar: Strategic approaches for first-in-human (FIH) studies and early clinical development

48:56

Navigating the new EU CTR in early phase clinical trials

56:50

Studies with 13C- and 14C-labelled investigational medicinal products in humans

45:28

FDA Waivers for TQT Studies

A drug's propensity to cause QT prolongation has to be carefully evaluated in the course of clinical development, and until recently, regulators have required a designated study, the thorough QT (TQT) study, to rule out a small QT effect. It has howe

1:00:02